AVEOAveo Pharmaceuticals

$-0.02 (-3%)

Aveo Pharmaceuticals (AVEO) Stock Analysis

Create a FREE Account to View Full AVEO Stock Report

Aveo Pharmaceuticals (AVEO) Analyst Forecast

Next 12 months ➝Current Price$0.6452-week High$1.9852-week Low$0.47MEAN$1.92+201.45%HIGH$2.00+214.66%LOW$1.75+175.33%
  • Last Price$0.64
  • Previous Close$0.66
  • Change $-0.02
  • Open$0.66
  • Volume1,756,051
  • Avg. Volume (100-day)2,228,255
  • Market Capitalization$102.22M
  • Days Range $0.63 - $0.67
  • 52-week Range $0.47 - $1.98
  • Dividend Yield
  • Ex. Dividend Date
  • P-E10.8
  • EPS0.06
  • Earnings Date03/12/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta2.593
  • PEG Ratio
  • Volatility0.83
  • Average True Range0.07
AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.